title: Effect of verapamil on ischemia and ventricular arrhythmias after an acute myocardial infarction: prognostic implications. The Danish Verapamil Infarction Trial II Study Group.
abstract: This article is a review of presented subsets of the Danish Verapamil Infarction Trial II (DAVIT II) regarding the effect of verapamil on postinfarction ischemia, ventricular arrhythmias, and heart rate (HR), and the prognostic implications of these findings. Patients underwent Holter monitoring for 24-48 h at 1 week, i.e., before randomization to long-term treatment with placebo or verapamil, and after 1 month and about 1 year of study treatment. Ischemia: 18% of the patients had transient ST-segment deviation before randomization; 24% of the placebo- and 8% of the verapamil-treated patients (p = 0.04) showed ischemia after 1 month; and after 1 year, the figures were 26 and 4%, respectively (p = 0.02). The 18-month major event rate, i.e., first reinfarction or death, in patients with ischemia before randomization were 40 and 23.8% in patients without ischemia (p = 0.06). Arrhythmias: In the placebo group the prevalence and incidence of many ventricular ectopic beats (VEBs), i.e., more than 10 VEBs/h, increased significantly during the first years after infarction; this was not the case in the verapamil patients group. The mean HR was significantly reduced by verapamil treatment after 1 month and after 16 months of treatment. Multivariate analysis demonstrated the presence of more than 10 VEBs/h only early (i.e., 1 week) but not late (i.e., 1 month) after infarction, to be an independent predictor of major events during 18 months' follow-up observation. A HR above 80 beats/min independently predicted major events when appearing both early and late after infarction.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiology, Hvidovre University Hospital, Denmark.
authors.forename: M
authors.initials: M
authors.lastname: Vaage-Nilsen
authors.forename: V
authors.initials: V
authors.lastname: Rasmussen
authors.forename: J F
authors.initials: JF
authors.lastname: Hansen
authors.forename: L
authors.initials: L
authors.lastname: Hagerup
authors.forename: M B
authors.initials: MB
authors.lastname: Sørensen
authors.forename: O P
authors.initials: OP
authors.lastname: Bjergaard
authors.forename: K
authors.initials: K
authors.lastname: Mellemgaard
authors.forename: N H
authors.initials: NH
authors.lastname: Holländer
authors.forename: I
authors.initials: I
authors.lastname: Nielsen
authors.forename: B
authors.initials: B
authors.lastname: Sigurd
mesh_terms: D000704:Analysis of Variance; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy*; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy*; D011379:Prognosis; D014700:Verapamil / Q000627:therapeutic use*
chemical_list: D014700:Verapamil